BioMarin Pharmaceuticals
BMRN
553 hedge funds and large institutions have $12.7B invested in BioMarin Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 86 funds opening new positions, 198 increasing their positions, 198 reducing their positions, and 86 closing their positions.
36% more call options, than puts
Call options by funds: $152M | Put options by funds: $112M
0% more first-time investments, than exits
New positions opened: 86 | Existing positions closed: 86
0% more repeat investments, than reductions
Existing positions increased: 198 | Existing positions reduced: 198
1% less funds holding
Funds holding: 558 → 553 (-5)
2.56% less ownership
Funds ownership: 97.34% → 94.78% (-2.6%)
17% less capital invested
Capital invested by funds: $15.2B → $12.7B (-$2.54B)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$225M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$95.4M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$67.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$54M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$45.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$211M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$90.6M |
| 3 |
Barclays
London,
United Kingdom
|
-$69.4M |
| 4 |
State Street
Boston,
Massachusetts
|
-$68M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$62.2M |
BMRN Hedge Fund Activity: Q3 2024 in Review
553 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2024, worth a combined $12.7B — down 17% from $15.2B a quarter earlier.
Fund positioning in BMRN was balanced in Q3 2024: 86 funds opened new positions, 86 closed out, 198 added to existing stakes and 198 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $225M. The largest seller was Avoro Capital Advisors, cutting an estimated $211M.
- 553 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2024, down from 558 in Q2 2024.
- Funds reported $12.7B of BioMarin Pharmaceuticals stock for Q3 2024, down 17% quarter-over-quarter.
- 86 funds opened new BioMarin Pharmaceuticals positions in Q3 2024 and 86 closed out, a net change of 0 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2024 was Viking Global Investors, an estimated $225M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2024 was Avoro Capital Advisors, an estimated $211M sold.
Based on aggregated 13F filings for Q3 2024.